<DOC>
	<DOCNO>NCT00492440</DOCNO>
	<brief_summary>RATIONALE : Interleukin-7 may stimulate white blood cell kill tumor cell . PURPOSE : This phase I trial study side effect best dose interleukin-7 treating patient metastatic melanoma locally advance metastatic kidney cancer .</brief_summary>
	<brief_title>Interleukin-7 Treating Patients With Metastatic Melanoma Locally Advanced Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety recombinant interleukin-7 ( IL-7 ) patient metastatic melanoma locally advance metastatic renal cell carcinoma . - Confirm previously document safety profile non-glycosylated IL-7 patient . - Determine safety high dos recombinant IL-7 patient . - Determine maximum tolerate dose recombinant IL-7 patient . - Determine biologically active dose recombinant IL-7 patient . Secondary - Determine pharmacokinetics pharmacodynamics recombinant IL-7 patient . - Compare biological clinical effect recombinant IL-7 non-glycosylated IL-7 patient . - Determine potential antitumor effect recombinant IL-7 patient . - Determine dose administration schedule recombinant IL-7 patient . OUTLINE : This dose-escalation study . Patients stratify accord lymphocyte count ( normal lymphocyte count [ CD4+ T cell &gt; 400/mm^3 ] v lymphopenic [ CD4+ T cell &lt; 400/mm^3 ] ) . Patients assign 1 2 treatment group . - Group 1 ( normal lymphocyte count ) : Patients receive recombinant interleukin-7 ( IL-7 ) subcutaneously week ( determine active dose ) 3 week absence disease progression unacceptable toxicity . - Group 2 ( lymphopenic ) : Patients receive recombinant IL-7 subcutaneously week 3 week one dose level active dose determine group 1 . Cohorts 3-6 patient group receive escalate dos recombinant IL-7 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Up 30 additional patient may treat MTD . Patients undergo blood bone marrow collection periodically pharmacokinetic , pharmacodynamic , immunological study . Samples analyze presence antibody proteins via ELISA ; CD3 , CD4 , CD8 T cell count , CD127 , Ki-67 , Bcl-2 expression CD4+ CD8+ T cell , CD19 B cell count via flow cytometry ; clonal B cell proliferation via PCR flow cytometry . After completion study treatment , patient follow 3 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Melanoma Metastatic disease Renal cell carcinoma Locally advance unresectable disease OR metastatic disease Refractory standard therapy OR ineligible receive standard therapy Measurable evaluable disease Previously receive highdose interleukin2 OR contraindication treatment No previously untreated unstable brain metastases No splenic metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 3 month Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm^3 PT/PTT ≤ 1.5 time upper limit normal ( ULN ) Creatinine &lt; 1.5 time ULN AST ALT &lt; 2.5 time ULN Conjugated ( Direct ) bilirubin ≤ 1.25 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception LVEF ≥ 45 % cardiac stress test ( e.g. , stress thallium , stress MUGA , dobutamine echocardiogram , stress test ) patient meet follow criterion : History ECG abnormalities Symptoms cardiac ischemia At least 50 year age Familial personal history heart failure Previously treat antimitotic agent susceptible trigger heart failure FEV_1 &gt; 60 % predict ( patient prolong smoke history symptom respiratory dysfunction ) No concurrent cognitive impairment likelihood develop cognitive impairment study therapy No concurrent splenomegaly proliferative hematologic disease No document HIV positivity No acute hepatitis A hepatitis B C Positive hepatitis B serology indicative previous immunization ( i.e. , HBs Ab positive HBc Ab negative ) allow Positive hepatitis C serology allow provide HCV RNA load PCR negative Resting blood pressure ≤ 140/90 mm Hg standard antihypertensive therapy Untreated hypertensive patient receive standard antihypertensive therapy allow provide hypertension well control No QTc prolongation ≥ 470 msec No prior history cardiovascular disease , arrhythmia , significant ECG abnormalities No active infection require systemic treatment and/or hospitalization within past 28 day Patients complete therapy clinically stable therapy , opinion investigator , eligible No history autoimmune disease No history severe asthma No history medical psychiatric disease would preclude study treatment No document cirrhosis document acute hepatitis PRIOR CONCURRENT THERAPY : See Disease Characteristics More 2 week since prior systemic corticosteroid therapy More 4 week since prior concurrent cytotoxic therapy , immunotherapy , biological agent ( i.e. , cytokine , growth factor , monoclonal antibody ) , antitumor vaccine More 7 day since prior hepatotoxic drug unless medically necessary More 2 day since prior alcohol consumption More 1 day since prior acetaminophen use No prior splenectomy No prior allogeneic hematopoietic stem cell transplantation solid organ transplantation No concurrent palliative therapy No concurrent chemotherapy No concurrent chronic anticoagulation ( i.e. , highdose warfarin heparin ) Warfarin dose 1 2 mg/day allow No concurrent chronic medication asthma No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>